Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
Economics Highlights: Elon Musk & Eli Lilly | FDA approves world’s most expensive drug | Medicare cuts
Tuesday, December 6, 2022
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Editor's Choice: Economics

Elon Musk and Eli Lilly: How a fake tweet caused chaos and reignited the debate over insulin prices

Updated Twitter policies have helped online pranksters cause mischief in recent days, including one specific user who impersonated Eli Lilly and Company and posted that insulin was now free. Lilly's CEO has now commented on the fake tweet read 'round the world—and what it could mean for the company going forward. 

READ MORE >
Smartphone mHealth. Updated Twitter policies have helped online pranksters cause mischief in recent days, including one specific user who impersonated Eli Lilly and Company and posted that insulin was now free. Lilly CEO has now commented on the fake tweet read 'round the world—and what it could mean for the company going forward. 
Share on Twitter Share on Facebook Share on Linkedin

Elon Musk and Eli Lilly: How a fake tweet caused chaos and reignited the debate over insulin prices

Share on Twitter Share on Facebook Share on Linkedin
Smartphone mHealth. Updated Twitter policies have helped online pranksters cause mischief in recent days, including one specific user who impersonated Eli Lilly and Company and posted that insulin was now free. Lilly CEO has now commented on the fake tweet read 'round the world—and what it could mean for the company going forward. 
Updated Twitter policies have helped online pranksters cause mischief in recent days, including one specific user who impersonated Eli Lilly and Company and posted that insulin was now free. Lilly's CEO has now commented on the fake tweet read 'round the world—and what it could mean for the company going forward. 
READ MORE >

FDA approves world’s most expensive drug, a hemophilia B treatment expected to cost $3.5M

The single-dose gene therapy can help patients reduce their risk of bleeding events and discontinue factor IX prophylaxis therapy.

READ MORE >
Money dollar investments
Share on Twitter Share on Facebook Share on Linkedin

FDA approves world’s most expensive drug, a hemophilia B treatment expected to cost $3.5M

Share on Twitter Share on Facebook Share on Linkedin
Money dollar investments
The single-dose gene therapy can help patients reduce their risk of bleeding events and discontinue factor IX prophylaxis therapy.
READ MORE >

FDA Commissioner Robert Califf calls on cardiology to address health inequities and combat misinformation

FDA Commissioner Robert Califf, MD, who is a cardiologist, spoke at the opening session of the American Heart Association about the need to step up and address two major problems in the American healthcare system. 

READ MORE >
U.S. Food and Drug Administration Commissioner Robert Califf, MD, who is a cardiologist, spoke at the opening session of the American Heart Association (AHA) last week about the need for doctors and health systems to step up to address two major problems - misinformation and health disparities.
Share on Twitter Share on Facebook Share on Linkedin

FDA Commissioner Robert Califf calls on cardiology to address health inequities and combat misinformation

Share on Twitter Share on Facebook Share on Linkedin
U.S. Food and Drug Administration Commissioner Robert Califf, MD, who is a cardiologist, spoke at the opening session of the American Heart Association (AHA) last week about the need for doctors and health systems to step up to address two major problems - misinformation and health disparities.
FDA Commissioner Robert Califf, MD, who is a cardiologist, spoke at the opening session of the American Heart Association about the need to step up and address two major problems in the American healthcare system. 
READ MORE >

VIDEO: ACC president says Medicare cuts should be a call to action across healthcare

American College of Cardiology President Edward Fry, MD, spoke about recent Medicare cuts at the American Heart Association Scientific Sessions conference in Chicago. 

READ MORE >
ACC President Ed Fry, MD, an interventional and general cardiologist at Ascension St. Vincent Hospital in Indianapolis, Indiana, and chair of the Ascension National Cardiovascular Service Line, says Medicare cuts for 2023 are a tipping point that need to be a call to action across medicine. #AHA22 #ACC
Share on Twitter Share on Facebook Share on Linkedin

VIDEO: ACC president says Medicare cuts should be a call to action across healthcare

Share on Twitter Share on Facebook Share on Linkedin
ACC President Ed Fry, MD, an interventional and general cardiologist at Ascension St. Vincent Hospital in Indianapolis, Indiana, and chair of the Ascension National Cardiovascular Service Line, says Medicare cuts for 2023 are a tipping point that need to be a call to action across medicine. #AHA22 #ACC
American College of Cardiology President Edward Fry, MD, spoke about recent Medicare cuts at the American Heart Association Scientific Sessions conference in Chicago. 
READ MORE >

High copays keep many heart failure patients from filling needed prescriptions

Researchers examined data from more than 900 patients, presenting their findings in the Journal of the American Heart Association.

READ MORE >
Researchers examined data from more than 900 patients, presenting their findings in the Journal of the American Heart Association. Money and healthcare spending and econimics.
Share on Twitter Share on Facebook Share on Linkedin

High copays keep many heart failure patients from filling needed prescriptions

Share on Twitter Share on Facebook Share on Linkedin
Researchers examined data from more than 900 patients, presenting their findings in the Journal of the American Heart Association. Money and healthcare spending and econimics.
Researchers examined data from more than 900 patients, presenting their findings in the Journal of the American Heart Association.
READ MORE >

In Case You Missed It

Johnson & Johnson to acquire Abiomed in $16.6B deal

Johnson & Johnson agreed to an upfront payment of $380 per share. Abiomed shareholders can also receive up to an additional $35 per share if certain milestones are met in the years ahead. 

READ MORE >
Money dollar investments
Share on Twitter Share on Facebook Share on Linkedin

Johnson & Johnson to acquire Abiomed in $16.6B deal

Share on Twitter Share on Facebook Share on Linkedin
Money dollar investments
Johnson & Johnson agreed to an upfront payment of $380 per share. Abiomed shareholders can also receive up to an additional $35 per share if certain milestones are met in the years ahead. 
READ MORE >

Cordis to acquire MedAlliance, known for its drug-eluting balloons, in deal that could surpass $1B

The acquisition includes an initial investment of $35 million and an upfront closing payment of $200 million. By 2029, if the companies reach all targeted regulatory and commercial milestones, the acquisition could cost Cordis up to $1.135 billion in all.

READ MORE >
Cordis acquires MedAlliance, known for its drug-eluting balloon technology, in deal that could surpass $1B
Share on Twitter Share on Facebook Share on Linkedin

Cordis to acquire MedAlliance, known for its drug-eluting balloons, in deal that could surpass $1B

Share on Twitter Share on Facebook Share on Linkedin
Cordis acquires MedAlliance, known for its drug-eluting balloon technology, in deal that could surpass $1B
The acquisition includes an initial investment of $35 million and an upfront closing payment of $200 million. By 2029, if the companies reach all targeted regulatory and commercial milestones, the acquisition could cost Cordis up to $1.135 billion in all.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
M&A activity in cardiology: Exploring key trends | Cardiac PET vs. SPECT | Doctors support Medicare covering TAVR for AR
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme